Is There a Role for Antiinflammatory Treatment in COPD?

REFERENCES

• GOLD Executive Summary. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2003 update. 1–42, NIH Publication 2003
   Google Scholar
• Saetta M, Di Stefano A, Turato G, et al. CD8+ T-Lymphocytes in Peripheral Airways of Smokers with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1998; 157: 822–826
   PubMed Web of Science ®Google Scholar
• Stockley R A. Neutrophils and the pathogenesis of COPD. Chest 2002; 121: 151S–155S
   PubMed Web of Science ®Google Scholar
• Thurlbeck W M. Pathology of chronic obstructive pulmonary disease. Clin Chest Med 1990; 11: 389–404
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitiation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277–1285
   PubMed Web of Science ®Google Scholar
• Peleman R A, Rytila P H, Kips J C, et al. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 839–843
   PubMed Web of Science ®Google Scholar
• Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015–1022
   PubMed Web of Science ®Google Scholar
• Heaney L G, Lindsay J T, McGarvey L P. Inflammation in chronic obstructive pulmonary disease: implications for new treatment strategies. Curr Med Chem 2007; 14: 787–796
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Connett J E, Kiley J P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA 1994; 272: 1497–1505
   PubMed Web of Science ®Google Scholar
• Gamble E, Grootendorst D C, Hattotuwa K, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007; 30: 467–471
   PubMed Web of Science ®Google Scholar
• Hogg J C, Chu F SF, Tan W C, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 176: 454–459
   Web of Science ®Google Scholar
• Washko G R, Fan V S, Ramsey S D, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 177: 164–169
   PubMed Web of Science ®Google Scholar
• Powrie D J, Wilkinson T MA, Donaldson G C, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30: 472–478
   PubMed Web of Science ®Google Scholar
• Cazzola M, Mac Nee W, Martinez F J, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416–468
   PubMed Web of Science ®Google Scholar
• Sin D D, Man S FP, Marciniuk D, et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? - study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmon Med 2006; 6: 3
   PubMedGoogle Scholar
• Grootendorst D C, Gauw S A, Verhoosel R M, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081–1087
   PubMed Web of Science ®Google Scholar
• Gamble E, Grootendorst D C, Brightling C E, et al. Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in COPD. Am J Respir Crit Care Med 2003; 168: 976–982
   PubMed Web of Science ®Google Scholar
• Calverley P MA, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154–161
   PubMed Web of Science ®Google Scholar
• Brusasco V. Airway inflammation in COPD. Friend or foe ?. Am J Respir Crit Care Med 2008; 176: 425–429
   Web of Science ®Google Scholar
• Zuwallack R L, Haggerty M C, Jones P. Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease. Am J Med 2004; 117: 49S–59S
   PubMedGoogle Scholar
• Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144–149
   PubMed Web of Science ®Google Scholar
• Calverley P MA, Anderson J A, Celli B R, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789
   PubMed Web of Science ®Google Scholar
• Wedzicha J A, Calverley P MA, Seemungal T AR, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19–26
   PubMed Web of Science ®Google Scholar
• Baraldo S, Turato G, Badin C, et al. Neutrophilic infiltration within the airway smooth muscle in patients with COPD. Thorax 2004; 59: 308–312
   PubMed Web of Science ®Google Scholar
• Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease—Relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105–110
   PubMed Web of Science ®Google Scholar
• O'Donnell R A, Peebles C, Ward J A, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837–842
   PubMed Web of Science ®Google Scholar
• Beeh K M, Beier J, Kornmann O, et al. Long-term repeatability of induced sputum inflammatory markers in stable, moderately severe COPD. Chest 2003; 123: 778–783
   PubMed Web of Science ®Google Scholar
• Lapperre T S, Snoeck-Stroband B, Gosman M ME, et al. Dissociation of lung function and airway inflammation in chronic onstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 499–504
   PubMed Web of Science ®Google Scholar
• Hogg J C, Chu F, Utokaparch S, et al. The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. N Engl J Med 2004; 350: 2645–2653
   PubMed Web of Science ®Google Scholar
• Wempe J B, Postma D S, Breederveld N, et al. Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease. Thorax 1992; 47: 616–621
   PubMed Web of Science ®Google Scholar
• Auffarth B, Postma D S, de Monchy J G, et al. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax 1991; 46: 372–377
   PubMed Web of Science ®Google Scholar
• Wesseling G J, Quaedvlieg M, Wouters E FM. Inhaled budesonide in chronic bronchitis. Effects on respiratory impedance. Eur Respir J 1991; 4: 1101–1105
   PubMed Web of Science ®Google Scholar
• Engel T, Heinig J H, Madsen O, et al. A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis. Eur Respir J 1989; 2: 935–939
   PubMed Web of Science ®Google Scholar
• Watson A, Lim T K, Joyce H, et al. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest 1992; 101: 350–355
   PubMed Web of Science ®Google Scholar
• Weiner P, Weiner M, Azgad Y, et al. Inhaled budesonide therapy for patients with stable COPD. Chest 1998; 108: 1568–1571
   Google Scholar
• Thompson A B, Mueller M B, Heires A J, et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992; 146: 389–395
   PubMed Web of Science ®Google Scholar
• Thompson W H, Carvalho P, Souza J P, et al. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD. Lung 2002; 180: 191–201
   PubMed Web of Science ®Google Scholar
• Nishimura K, Koyama H, Ikeda A, et al. The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD. Chest 1999; 115: 31–37
   PubMed Web of Science ®Google Scholar
• Mahler D A, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084–1091
   PubMed Web of Science ®Google Scholar
• Hanania N A, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124: 834–843
   PubMed Web of Science ®Google Scholar
• Calverley P MA, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456
   PubMed Web of Science ®Google Scholar
• Calverley P MA, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–919
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Rouleau M Y, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 477–482
   PubMed Web of Science ®Google Scholar
• Van Der Valk P, Monninkhof E, van der Palen J, et al. Effect of Discontinuation of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: The COPE Study. Am J Respir Crit Care Med 2002; 166: 1358–1363
   PubMed Web of Science ®Google Scholar
• Sin D D, Mac Alister F A, Man S FP, et al. Contemporary Management of chronic obstructive pulmonary disease. JAMA 2003; 290: 2301–2312
   PubMed Web of Science ®Google Scholar
• Redelmeier D A, Goldstein R S, Min S T, et al. Spirometry and dyspnea in patients with COPD. When small differences mean little. Chest 1996; 109: 1163–1168
   PubMed Web of Science ®Google Scholar
• Weir D C, Bale G A, Bright P, et al. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in aptients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy 1999; 29(supplement 2)125–128
   PubMedGoogle Scholar
• Paggiaro P L, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773–780
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81
   PubMed Web of Science ®Google Scholar
• O'Brien A, Russo-Magno P, Karki A, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001; 164: 365–371
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler D A, Jones P W, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–224
   PubMed Web of Science ®Google Scholar
• Vincken W, Van Noord J A, Greefhorst A PM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209–216
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007; 62: 938–943
   PubMed Web of Science ®Google Scholar
• Sin D D, Man S F. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol 2006; 533: 28–35
   PubMed Web of Science ®Google Scholar
• Aksoy M O, Mardini I A, Yang Y, et al. Glucocorticoid effects on the beta-adrenergic receptor-adenylyl cyclase system of human airway epithelium. J Allergy Clin Immunol 2002; 109: 491–497
   PubMed Web of Science ®Google Scholar
• Giannini D, Bacci E, Dente F L, et al. Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge. Chest 1999; 115: 629–634
   PubMed Web of Science ®Google Scholar
• Yates D H, Kharitonov S A, Barnes P J. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled ß2-agonist. Am J Respir Crit Care Med 1996; 154: 1603–1607
   PubMed Web of Science ®Google Scholar
• Kalra S, Swystun V A, Bhagat R, et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953–956
   PubMed Web of Science ®Google Scholar
• Grootendorst D C, Sterk P J, Heijerman H G. Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma. Eur Respir J 2001; 17: 374–379
   PubMed Web of Science ®Google Scholar
• Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51: 267–271
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996; 153: 1530–1535
   PubMed Web of Science ®Google Scholar
• Rutgers S R, Postma D S, ten Hacken N H, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55(1)12–18
   PubMed Web of Science ®Google Scholar
• Hogg J C. Why does airway inflammation persist after the smoking stops?. Thorax 2006; 61: 96–97
   PubMed Web of Science ®Google Scholar
• Senderovitz T, Vestbo J, Frandsen J, et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respir Med 1999; 93: 715–718
   PubMed Web of Science ®Google Scholar
• Kerstjens H AM, Brand P LP, Hughes M D, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327: 1413–1419
   PubMed Web of Science ®Google Scholar
• Derenne J P. Effects of high-dose inhaled beclomethasone on the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2-year prospective multicentre study. Am J Respir Crit Care Med 1995; 151: A463, (Abstract)
   Google Scholar
• Renkema T EJ, Schouten J P, Koeter G H, et al. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156–1162
   PubMed Web of Science ®Google Scholar
• Dompeling E, Van Schayck C P, Molema J, et al. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992; 5: 945–952
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sorensen T IA, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–1823
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Lofdahl C G, Laitinen L A, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948–1953
   PubMed Web of Science ®Google Scholar
• The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902–1909
   PubMed Web of Science ®Google Scholar
• Burge P S, Calverley P M, Jones P W, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320(7245)1297–1303
   PubMed Web of Science ®Google Scholar
• Highland K B, Strange C, Heffner J E. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease - A meta-analysis. Ann Intern Med 2003; 138: 969–973
   PubMed Web of Science ®Google Scholar
• Sutherland E R, Allmers H, Ayas N T, et al. Chronic obstructive pulmonary disease - Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58: 937–941
   PubMed Web of Science ®Google Scholar
• Wedzicha J A, Seemungal T AR. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786–796
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 968–975
   PubMed Web of Science ®Google Scholar
• Brightling C E, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356(9240)1480–1485
   PubMed Web of Science ®Google Scholar
• Hurst J R, Perera W R, Wilkinson T MA, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 71–78
   PubMed Web of Science ®Google Scholar
• Rohde G, Schlosser B, Arinir U, et al. The role of respiratory infections in chronic obstructive pulmonary disease. Med Klin 2007; 102: 893–898
   Web of Science ®Google Scholar
• Bhowmik A, Seemungal T AR, Sapsford R J, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114–120
   PubMed Web of Science ®Google Scholar
• Gompertz S, Bayley D L, Hill S L, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001; 56: 36–41
   PubMed Web of Science ®Google Scholar
• Jones P W, Willits L R, Burge P S, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68–73
   PubMed Web of Science ®Google Scholar
• Beeh K M, Beier J, Buhl R, et al. Wirksamkeit von Tiotropiumbromid (Spiriva®) bei verschiedenen Schweregraden der chronisch-obstruktiven Lungenerkrankung (COPD). Pneumologie 2006; 60: 341–346
   PubMedGoogle Scholar
• Mirici A, Bektas Y, Ozbakis G. Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clin Drug Invest 2001; 21: 835–842
   Web of Science ®Google Scholar
• Sin D D, Man S FP. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?. Eur Respir J 2003; 21: 260–266
   PubMed Web of Science ®Google Scholar
• Kiri V A, Pride N B, Soriano J B, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172: 460–464
   PubMed Web of Science ®Google Scholar
• Soriano J B, Kiri V A, Pride N B, et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2: 67–74
   PubMedGoogle Scholar
• Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. Immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49–53
   PubMed Web of Science ®Google Scholar
• Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 23: 391–395
   PubMed Web of Science ®Google Scholar
• Suissa S, McGhan R, Niewoehner D E, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 535–542
   PubMedGoogle Scholar
• Gizycki M J, Hattotuwa K L, Barnes N, et al. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002; 57: 799–803
   PubMed Web of Science ®Google Scholar
• Hattotuwa K L, Gizycki M J, Ansari T W, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. A double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592–1596
   PubMed Web of Science ®Google Scholar
• Verhoeven G T, Hegmans J PJJ, Mulder P GH, et al. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002; 57: 694–700
   PubMed Web of Science ®Google Scholar
• Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995; 154: 4719–4725
   PubMed Web of Science ®Google Scholar
• Barnes N C, Qiu Y S, Pavord I D, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736–743
   PubMed Web of Science ®Google Scholar
• Sugiura H, Ichinose M, Yamagata S, et al. Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD. Thorax 2003; 58: 299–305
   PubMed Web of Science ®Google Scholar
• Keatings V M, Jatakanon A, Worsdell Y M, et al. Effects of inhaled and oral glucocorticosteroids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542–548
   PubMed Web of Science ®Google Scholar
• Culpitt S V, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635–1639
   PubMed Web of Science ®Google Scholar
• Loppow D, Schleiss M B, Kanniess F, et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001; 95: 115–121
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583–585
   PubMed Web of Science ®Google Scholar
• Yildiz F, Kaur A C, Ilgazli A, et al. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000; 67: 71–76
   PubMed Web of Science ®Google Scholar
• Ozol D, Aysan T, Solak Z A, et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients, Respir Med 2005;epub ahead of print
   Google Scholar
• Balbi B, Majori M, Bertacco S, et al. Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation?. Chest 2000; 117: 1633–1637
   PubMed Web of Science ®Google Scholar
• Groenke L, Beeh K M, Cameron R, et al. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008; 21: 409–417
   PubMed Web of Science ®Google Scholar
• Lipworth B J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167–175
   PubMed Web of Science ®Google Scholar
• Giembycz M A. Phosphodiesterase-4: Selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 326–333
   PubMedGoogle Scholar
• Rennard S I, Schachter N, Strek M, et al. Cilomilast for COPD: Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006; 129: 56–66
   PubMed Web of Science ®Google Scholar
• Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Clin Pharmacol 2006; 533: 110–117
   Web of Science ®Google Scholar
• Rabe K F, Bateman E D, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563–571
   PubMed Web of Science ®Google Scholar